Misha Petkevich, PhD

Co-founded V2M® Capital LLC’s predecessor firm BladeRock Capital, LLC in 2005. He was previously Chairman and Chief Executive Officer of The Petkevich Group, LLC, a small merchant bank focused on providing specialized services to and executing transactions for life science, information technology, and consumer related emerging growth companies.

Before founding The Petkevich Group, Dr. Petkevich was a Managing Director and Head of Investment Banking at Robertson Stephens & Co. where he served on the Management Committee, the Commitment Committee, and the Fairness Opinion Review Committee. Prior to Robertson Stephens, he held positions as an Institutional Investor ranked securities analyst and as an investment banker at Hambrecht & Quist and worked closely with the Life Sciences Venture Group.

Dr. Petkevich was awarded a Doctorate in Cell Biology from Oxford University where he attended as a Rhodes Scholar. He received an AB degree cum laude from Harvard College. Following Oxford, Dr. Petkevich studied music privately, was a Fellow in the Music Department at Harvard, and was Composer-in-Residence at Eliot House, Harvard University. He represented the United States in the 1968 and 1972 Winter Olympics, was U.S. and North American Figure Skating Champion, was a Gold Medalist at the World University Games and authored two books on skating. In 1972, he was the second recipient of the coveted Button-Salchow Trophy. Dr. Petkevich is on the Boards of Hinge Bio, Inc. and Cohbar, Inc. and previously served on the Boards of Advanced Bionics Corporation and Telios Pharmaceuticals, Inc. He is on the Board of Trustees for the United States Figure Skating Foundation, is Treasurer, and is Chairman of the investment Committee. He has served on the Advisory Board of the Gladstone Institute, on the Board of the San Francisco Opera, and on the Foundation Board of UCSF.

In 1970, Dr. Petkevich conceived of “An Evening with Champions”, a skating exhibition at Harvard run by the students to raise money for the Dana Farber Cancer Research Institute – The Jimmy Fund. The show has feature hundreds of National, World and Olympic Medalists and continues to this day raising over $2.5 million for the Jimmy Fund.


Annalisa Jenkins, M.B.B.S., F.R.C.P. Chief Executive Officer

Dr. Annalisa Jenkins has over 20 years of biopharmaceutical industry experience and is CEO of PlaqueTec. Prior to Plaquetec, she was CEO of Dimension Therapeutics, was head of global research and development at Merck Serono and held several senior positions at Bristol Myers-Squibb.

Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years - including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, Cocoon Biotech Inc. (Non Executive Chair), OncoSec, Vium, Inc. (Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Advisory Board

Sam Saks, MD

Director of many biopharma companies and was Chief Executive of Jazz Pharmaceuticals and company group Chairman of ALZA Corporation.

Between 2003 and April 2009, Dr. Saks was the chief executive officer and a director of Jazz Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, which he co-founded in 2003. From April 2011 until February 2012, Dr. Saks served as interim Chief Medical Officer of Threshold Pharmaceuticals, a publicly-held biopharmaceutical company. Between November 2013 and May 2015, Dr. Saks served as the Chief Development Officer of Auspex Pharmaceuticals, Inc., a publicly-held biopharmaceutical company. From 2001 until 2003, Dr. Saks was company group chairman of ALZA Corporation and a member of the Johnson & Johnson Pharmaceuticals Operating Committee. From 1992 until 2001, Dr. Saks held various positions at ALZA, including Chief Medical Officer and Group Vice President, where he was responsible for clinical, regulatory and commercial activities. Previously, Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks formerly served as a scientific advisor to ArQule Pharmaceuticals, CMEA Ventures and ProQuest Investments. Dr. Saks is currently a director of Velocity Pharmaceutical Development LLC (since 2011), Bullet Biotechnology, Inc. (since 2012), NuMedii (since 2013) and PDL BioPharma, Inc. (since September 2015). Dr. Saks served as a director of Depomed, Inc. (2012 – 2017), Auspex Pharmaceuticals, Inc. (2009 – 2015), Trubion Pharmaceuticals, Inc. (2005 – 2010), Corixa Corporation, Cougar Biotechnology, Inc., Coulter Pharmaceuticals, Inc., Ilypsa, Inc. and Sirna Therapeutics Inc. (formerly, Ribozyme Pharmaceuticals, Inc.). Dr. Saks is board certified in oncology and received a B.S. and an M.D. from the University of Illinois. Mr. Saks’ extensive scientific and medical expertise and experience in formulating partnering and business development strategies, including those involving larger pharmaceutical companies, was instrumental in his selection as a member of many Boards.

Advisory Board

Dr. Andrew Perlman

Founder, managing director and Chief Medical Officer of Velocity Pharmaceutical Development, an advisor to San Francisco based VC fund 8VC, and a member of the USC Dornsife College of Arts, Letters and Sciences Board of Councilors.

Dr. Andrew Perlman is a founder, managing director and Chief Medical Officer of Velocity Pharmaceutical Development, an advisor to San Francisco based VC fund 8VC, and a member of the USC Dornsife College of Arts, Letters and Sciences Board of Councilors. Dr. Perlman was an assistant professor of medicine at Stanford University prior to entering the biotechnology industry. He has had a notable career in drug development, significantly at Genentech, where as Senior Director of Clinical Research he played a key role in the development, FDA approval and marketing of human growth hormone. He was subsequently executive vice president at Tularik Inc. a small molecule drug discovery company. Following the acquisition of Tularik by Amgen he was a co-founder and CEO of Innate Immune Inc., an early stage biotech company focusing on therapies for asthma and autoimmune diseases. Dr Perlman has been on the board of directors of numerous private and public biotechnology companies. He has a BS from MIT and an MD-PhD from New York University.

Advisory Board